Vaginal progesterone as luteal phase support in natural cycle frozen-thawed embryo transfer (ProFET): protocol for a multicentre, open-label, randomised controlled trial.

Autor:	Stadelmann C; University of Gothenburg Institute of Clinical Sciences, Goteborg, Sweden caroline.stadelmann@vgregion.se.; Department of Obstetrics and Gynaecology, Sahlgrenska University Hospital, Gothenburg, Sweden., Bergh C; University of Gothenburg Institute of Clinical Sciences, Goteborg, Sweden.; Department of Obstetrics and Gynaecology, Sahlgrenska University Hospital, Gothenburg, Sweden., Brännström M; University of Gothenburg Institute of Clinical Sciences, Goteborg, Sweden.; Department of Obstetrics and Gynaecology, Sahlgrenska University Hospital, Gothenburg, Sweden., Olsen KH; Livio Fertility Center, Reykjavik, Iceland, Reykjavik, Iceland., Khatibi A; University of Gothenburg Institute of Clinical Sciences, Goteborg, Sweden.; Department of Obstetrics and Gynaecology, Sahlgrenska University Hospital, Gothenburg, Sweden., Kitlinski M; Department of Reproductive Medicine, Skåne University Hospital Malmö Reproductive Medicine Centre, Malmo, Sweden., Liffner S; Department of Biomedical and Clinical Sciences, Division of Children's and Women's Health, Linkoping University Hospital Obstetrics and Gynecology, Linkoping, Sweden., Lundborg E; Nordic IVF, Gothenburg, Sweden, Gothenburg, Sweden., Rodriguez-Wallberg KA; Department of Reproductive Medicine, Division of Gynecology and Reproduction, Karolinska Universitetssjukhuset, Stockholm, Sweden.; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Strandell A; University of Gothenburg Institute of Clinical Sciences, Goteborg, Sweden.; Department of Obstetrics and Gynaecology, Sahlgrenska University Hospital, Gothenburg, Sweden., Westlander G; Livio Fertility Center Göteborg, Goteborg, Sweden., Widlund G; Departement of Reproductive Medicine, University Hospital of Örebro, Sweden, Örebro universitet Fakulteten för medicin och hälsa, Örebro, Sweden., Magnusson Å; University of Gothenburg Institute of Clinical Sciences, Goteborg, Sweden.; Department of Obstetrics and Gynaecology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2022 Jul 08; Vol. 12 (7), pp. e062400. Date of Electronic Publication: 2022 Jul 08.
DOI:	10.1136/bmjopen-2022-062400
Abstrakt:	Introduction: Vaginal progesterone supplementation is frequently given to patients receiving frozen embryo transfer (FET) in the natural cycle aiming to increase the chance of pregnancy and live birth. To date, only a few studies have investigated if progesterone supplementation is beneficial in these cycles and the level of evidence for progesterone supplementation is very low. Methods and Analysis: The ProFET trial is a multicentre, open-label, randomised controlled trial powered for this investigation, including 1800 women with regular menstrual cycles (24-35 days), aged 18-43 years planned for natural cycle-FET receiving a single blastocyst for transfer. Participants are randomised (1:1:1) to either luteal phase progesterone for 3 weeks, luteal phase progesterone for 7 weeks or no luteal phase progesterone. The participating study centres consist of 12 in vitro fertilisation-clinics in Sweden and 1 in Iceland. The primary outcome is to investigate if luteal phase support (LPS) by vaginal progesterone increases the chance of a live birth per randomised patient in a natural FET cycle compared with no LPS. Ethics and Dissemination: The trial was approved by the Swedish Ethical Review Authority (ID 2020-06774, 2021-02822 and 2022-01502-02) and the Swedish Medical Products Agency (ID nr 5.1-2020-102613). All participants are required to provide written informed consent. The outcome of this study will be disseminated to the public through broadcasts, newspapers and presentations at scientific congresses as well as publications in international scientific journals. Trial Registration Number: NCT04725864. Competing Interests: Competing interests: CB and ÅM declare support from Ferring Pharmaceuticals, Merck Sereno and Gedeon Richter. MB has 4 % stocks in EUGIN Sweden. None of the other authors hade conflicts of interest. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu